Tumores Hepáticos 2016
Introduction
Benign liver tumours are a heterogeneous group of lesions with
different cellular origins, as summarized by an international
panel of experts sponsored by the World Congress of
Gastroenterology in 1994 [1]. These lesions are frequently found
incidentally as a consequence of the widespread use of imaging
tests and often have a benign course. Some of these lesions are
of greater clinical relevance than others, and the aim of these recommendations is to provide a contemporary aid for the practical
diagnosis and management of the more common benign
tumours. These include haemangiomas, focal nodular hyperplasia
(FNH) and hepatocellular adenoma (HCA).
The evidence and recommendations in these guidelines have
been graded according to the grading of the recommendations
assessment development and evaluation (GRADE) system [2].
The strength of recommendations reflects the quality of underlying evidence. The GRADE system offers two grades of recommendation: strong (1) or weak (2) (Table 1). The clinical practice
guidelines thus consider the quality of evidence: the higher the
quality of evidence, the more likely a strong recommendation is
warranted; the greater the variability in values and preferences,
or the greater the uncertainty, the more likely a weaker recommendation is warranted.
